Kolexia
Tavernier-Tardy Emmanuelle Hématologie
Tavernier-Tardy Emmanuelle
Hématologie
Institut de Cancérologie de la Loire Lucien Neuwirth
Saint-Priest-en-Jarez, France
166 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Leucémie-lymphome lymphoblastique à précurseurs B et T Syndromes myélodysplasiques Tumeurs hématologiques Chromosome Philadelphie Leucémie-lymphome lymphoblastique à précurseurs T Leucémie lymphoïde

Collaborateurs

Voir plus
Guyotat Denis
Guyotat Denis
Hôpital les Chanaux, Mâcon, France
Cornillon Jérôme
Cornillon Jérôme
Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez, France
Thomas Xavier
Thomas Xavier
Hôpital Lyon Sud, Pierre-Bénite, France
Dombret Herve
Dombret Herve
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Abbvie
6 collaboration(s)
Dernière en 2023
Novartis
6 collaboration(s)
Dernière en 2021
Janssen
3 collaboration(s)
Dernière en 2023
A+A
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Essai Clinique (Syros Pharmaceuticals)   11 mars 2024
FORMAT: Administration of Fibrinogen Concentrate for Refractory Bleeding in Hematological Patients With Intensive Chemotherapy-induced Thrombocytopenia - Analysis Using Viscoelastic Haemostatic Assay (FORMAT)
Essai Clinique (CHU Saint-Étienne)   01 mars 2024
ALFA2101: An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Essai Clinique (CHU Nice)   29 janvier 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Annals of hematology   26 janvier 2024
MENTALO: Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells: MENTALO Study
Essai Clinique (CHU Saint-Étienne)   15 janvier 2024
PHARM-LMC: Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia: PHARM-LMC Study
Essai Clinique (CHU Saint-Étienne)   09 janvier 2024
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment.
Leukemia & lymphoma   15 novembre 2023
Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1-Mutated Acute Myeloid Leukemia - a Filo Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)
65th ASH Annual Meeting Abstracts   02 novembre 2023